Table 3.
Supernatant rabies virus (RABV) antigen G concentration (IU/mL) at various time points post infection in MRC-5 with TPCA-1 treatment.
| MOI | 96 hpi | 168 hpi | 240 hpi | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| IU/mL | 0.05 | 0.1 | 0.5 | 0.05 | 0.1 | 0.5 | 0.05 | 0.1 | 0.5 | |
| MRC-5+ | 2.22 ± 0.30 | 2.23 ± 0.27 | 2.76 ± 0.11 | 2.76 ± 0.11 | 2.26 ± 0.26 | 2.32 ± 0.13 | 2.32 ± 0.10 | 2.61 ± 0.29 | 3.36 ± 0.14 | |
| MRC-5+ + TPCA-1 (0.5 μM) | 2.58 ± 0.22 | 2.09 ± 0.21 | 2.67 ± 0.12 | 2.87 ± 0.18 | 3.93 ± 0.19 | 4.49 ± 0.28 | 4.97 ± 0.25 | 4.81 ± 0.29 | 3.26 ± 0.34 | |
| MRC-5+ + TPCA-1 (1 μM) | 2.36 ± 0.10 | 3.07 ± 0.17 | 2.76 ± 0.04 | 4.74 ± 0.11 | 4.85 ± 0.23 | 4.44 ± 0.38 | 6.94 ± 0.19 | 7.19 ± 0.50 | 4.13 ± 0.36 | |
| MRC-5+ + TPCA-1 (4 μM) | 5.09 ± 0.40 | 4.74 ± 0.33 | 3.59 ± 0.38 | 7.12 ± 0.42 | 6.96 ± 0.44 | 4.27 ± 0.24 | 6.64 ± 0.56 | 5.78 ± 0.44 | 4.11 ± 0.22 | |